Forte Biosciences, Inc.
FBRX
$17.00
$1.338.49%
NASDAQ
| 03/31/2026 | 12/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -30.55% | -10.93% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -8.68% | 33.66% | |||
| Operating Income | 8.68% | -33.66% | |||
| Income Before Tax | 8.37% | -34.32% | |||
| Income Tax Expenses | -64.03% | -- | |||
| Earnings from Continuing Operations | 10.70% | -40.19% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 10.70% | -40.19% | |||
| EBIT | 8.68% | -33.66% | |||
| EBITDA | 8.68% | -33.68% | |||
| EPS Basic | 10.72% | -39.65% | |||
| Normalized Basic EPS | 7.43% | -32.41% | |||
| EPS Diluted | 10.72% | -39.65% | |||
| Normalized Diluted EPS | 7.43% | -32.41% | |||
| Average Basic Shares Outstanding | 0.03% | 0.39% | |||
| Average Diluted Shares Outstanding | 0.03% | 0.39% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||